Fate Therapeutics Inc (FATE)

[jondoeuk]

Now GILD https://www.fiercebiotech.com/biotech/gileads-kite-sails-vivo-car-t-space-350m-interius-buyout

In­terius' ther­a­py us­es a CD7-targeted lentivi­ral vec­tor and gen­er­ates both CAR-T and CAR-NK cells in the body, though the CAR-T cells far out­num­ber the CAR-NK cells https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(25)00487-3

The com­pa­ny was the first to dose a pa­tient without LD chemo as part of a PhI tri­al in Aus­tralia. In­terius, which is study­ing INT2104 (anti-CD20) in R/R B-cell malignancies, has al­so re­ceived ap­proval to start test­ing its ther­a­py in Spain and Ger­many. Be­fore the deal, the com­pa­ny was ex­pect­ed to re­port its first da­ta lat­er this year (likely ASH). In­terius has dosed six pa­tients to date, and the com­pa­ny shared the da­ta it has so far as part of the deal­ mak­ing process.